{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:39:09Z","timestamp":1792791549129,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["225412\/Z\/22\/Z"],"award-info":[{"award-number":["225412\/Z\/22\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.neuropharm.2026.111182","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:57:55Z","timestamp":1789052275000},"page":"111182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Glycine transporter 1 inhibitor, bitopertin, changes excitatory and inhibitory network connectivity in mouse medial prefrontal cortex"],"prefix":"10.1016","volume":"301","author":[{"given":"Martin","family":"Graf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Ponserre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8159-5461","authenticated-orcid":false,"given":"Sadra","family":"Sadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-6514","authenticated-orcid":false,"given":"Jamie","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7592-861X","authenticated-orcid":false,"given":"Madeleine","family":"Coy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0157-5138","authenticated-orcid":false,"given":"Anne","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ursu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1545-7267","authenticated-orcid":false,"given":"Azar","family":"Omrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Magno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Hengerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Rosenbrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Jung","family":"Chen-Engerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.111182_bib1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41593-019-0354-y","article-title":"A whole-brain atlas of monosynaptic input targeting four different cell types in the medial prefrontal cortex of the mouse","volume":"22","author":"\u00c4hrlund-Richter","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib2","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.neuropharm.2011.11.008","article-title":"Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia","volume":"62","author":"Alberati","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111182_bib3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41386-023-01769-z","article-title":"Activation of prefrontal parvalbumin interneurons ameliorates working memory deficit even under clinically comparable antipsychotic treatment in a mouse model of schizophrenia","volume":"49","author":"Arime","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2026.111182_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tins.2015.11.001","article-title":"Roles of presynaptic NMDA receptors in neurotransmission and plasticity","volume":"39","author":"Banerjee","year":"2016","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0893-133X(01)00225-1","article-title":"GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder","volume":"25","author":"Benes","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2026.111182_bib6","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.tins.2018.07.015","article-title":"Inhibitory interneurons regulate temporal precision and correlations in cortical circuits","volume":"41","author":"Cardin","year":"2018","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nature08002","article-title":"Driving fast-spiking cells induces gamma rhythm and controls sensory responses","volume":"459","author":"Cardin","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2026.111182_bib8","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1038\/npp.2014.4","article-title":"Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in Nonhuman Primates","volume":"39","author":"Castner","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2026.111182_bib9","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuroscience.2022.06.027","article-title":"Increasing the excitatory drive rescues Excitatory\/Inhibitory imbalance and mismatch negativity deficit caused by parvalbumin specific GluA1 deletion","volume":"496","author":"Chen-Engerer","year":"2022","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2026.111182_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175306","article-title":"Pro-cognitive effects of the GlyT1 inhibitor Bitopertin in rodents","volume":"935","author":"Deiana","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111182_bib12","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/jamapsychiatry.2023.2972","article-title":"Diagnostic specificity and association with cognition of molecular alterations in prefrontal somatostatin neurons in schizophrenia","volume":"80","author":"Dienel","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2026.111182_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.biopsych.2025.01.010","article-title":"Alterations in prefrontal cortical somatostatin neurons in schizophrenia: evidence for weaker inhibition of pyramidal Neuron dendrites","volume":"98","author":"Dienel","year":"2025","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2026.111182_bib14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41593-024-01834-w","article-title":"Mapping the cellular etiology of schizophrenia and complex brain phenotypes","volume":"28","author":"Duncan","year":"2025","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fncir.2018.00037","article-title":"PV interneurons: critical regulators of E\/I balance for prefrontal cortex-dependent behavior and psychiatric disorders","volume":"12","author":"Ferguson","year":"2018","journal-title":"Front. Neural Circ."},{"key":"10.1016\/j.neuropharm.2026.111182_bib16","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.3390\/molecules29246017","article-title":"Org24598, a selective glycine transporter 1 (GlyT1) inhibitor, reverses object recognition and spatial memory impairments following binge-like ethanol exposure in rats","volume":"29","author":"Filarowska-Jurko","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2026.111182_bib17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1093\/schbul\/sbs010","article-title":"NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia","volume":"38","author":"Gonzalez-Burgos","year":"2012","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2026.111182_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116821","article-title":"Mapping the functional connectome of the claustrum: noise filtering via local inhibitory circuits","volume":"45","author":"Graf","year":"2026","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2026.111182_bib19","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.1523\/JNEUROSCI.21-21-08362.2001","article-title":"Paired-pulse plasticity at the single release site level: an experimental and computational study","volume":"21","author":"Hanse","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/science.1255263","article-title":"Fast-spiking, parvalbumin+ GABAergic interneurons: from cellular design to microcircuit function","volume":"345","author":"Hu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2026.111182_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052345","article-title":"SUMOylation is required for glycine-induced increases in AMPA receptor surface expression (ChemLTP) in hippocampal neurons","volume":"8","author":"Jaafari","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2026.111182_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/JCP.0000000000000722","article-title":"Neurophysiological effects of Bitopertin in schizophrenia","volume":"37","author":"Kantrowitz","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2026.111182_bib23","doi-asserted-by":"crossref","first-page":"7586","DOI":"10.1523\/JNEUROSCI.23-20-07586.2003","article-title":"The Glycine transporter type 1 inhibitor N-[3-(4\u2032-Fluorophenyl)-3-(4\u2032-Phenylphenoxy)Propyl]Sarcosine potentiates NMDA receptor-mediated responses In Vivo and produces an antipsychotic profile in Rodent behavior","volume":"23","author":"Kinney","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41583-023-00724-7","article-title":"GABA tone regulation and its cognitive functions in the brain","volume":"24","author":"Koh","year":"2023","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fpsyt.2013.00052","article-title":"NMDA receptor activity in neuropsychiatric disorders","volume":"4","author":"Lakhan","year":"2013","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2026.111182_bib26","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.neuron.2013.10.031","article-title":"Pyramidal neurons in prefrontal cortex receive subtype-specific forms of excitation and inhibition","volume":"81","author":"Lee","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2026.111182_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tins.2011.10.004","article-title":"Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia","volume":"35","author":"Lewis","year":"2012","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib28","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fnmol.2016.00102","article-title":"Glycine potentiates AMPA receptor function through metabotropic activation of GluN2A-Containing NMDA receptors","volume":"9","author":"Li","year":"2016","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib29","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/s41380-023-01949-9","article-title":"Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment","volume":"28","author":"McCutcheon","year":"2023","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2026.111182_bib30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.biopsych.2008.11.019","article-title":"Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia","volume":"65","author":"Mellios","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2026.111182_bib31","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bcp.2011.02.003","article-title":"Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition","volume":"81","author":"M\u00f6hler","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111182_bib32","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1016\/j.neuron.2025.05.029","article-title":"Distinct dendritic integration strategies control dynamics of inhibition in the neocortex","volume":"113","author":"Morabito","year":"2025","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2026.111182_bib33","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/cercor\/bhm186","article-title":"Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder","volume":"18","author":"Morris","year":"2008","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2026.111182_bib34","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3390\/biom14091128","article-title":"Dysfunction of the NMDA receptor in the pathophysiology of schizophrenia and\/or the pathomechanisms of treatment-resistant schizophrenia","volume":"14","author":"Okubo","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.neuropharm.2026.111182_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.742058","article-title":"Directly and indirectly targeting the glycine modulatory site to modulate NMDA receptor function to address unmet medical needs of patients with schizophrenia","volume":"12","author":"Pei","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2026.111182_bib36","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.2174\/1381612821666150724100952","article-title":"Inhibition of glycine transporter 1: the yellow brick road to new schizophrenia therapy?","volume":"21","author":"Philipp","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuropharm.2026.111182_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2533\/chimia.2018.477","article-title":"Glycine transporter type I (GlyT1) inhibitor, bitopertin: a journey from lab to patient","volume":"72","author":"Pinard","year":"2018","journal-title":"Chimia"},{"key":"10.1016\/j.neuropharm.2026.111182_bib38","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1007\/s00406-023-01576-z","article-title":"Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia","volume":"273","author":"Rosenbrock","year":"2023","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.121.001071","article-title":"Effects of the glycine Transporter-1 Inhibitor iclepertin (BI 425809) on sensory processing, neural network function, and cognition in animal models related to Schizophrenia","volume":"382","author":"Rosenbrock","year":"2022","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2026.111182_bib40","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/s41380-019-0426-0","article-title":"Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders","volume":"24","author":"Sohal","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2026.111182_bib41","doi-asserted-by":"crossref","first-page":"7319","DOI":"10.1073\/pnas.1232232100","article-title":"In vivo two-photon calcium imaging of neuronal networks","volume":"100","author":"Stosiek","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib42","first-page":"120","article-title":"Russell and burch's 3Rs then and now: the need for clarity in definition and purpose","volume":"54","author":"Tannenbaum","year":"2015","journal-title":"JAALAS"},{"key":"10.1016\/j.neuropharm.2026.111182_bib43","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/schbul\/sbae180","article-title":"N-Methyl-d-Aspartate receptor antibody and sensory gating deficits in non-smoking, minimal antipsychotic medication exposure, and first-episode patients with schizophrenia","volume":"51","author":"Tong","year":"2024","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2026.111182_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116298","article-title":"The excitatory-inhibitory balance as a target for the development of novel drugs to treat schizophrenia","volume":"228","author":"Uliana","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111182_bib45","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, Double-Blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.neuropharm.2026.111182_bib46","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/schbul\/sbaa184","article-title":"A role for somatostatin-positive interneurons in Neuro-Oscillatory and information processing deficits in schizophrenia","volume":"47","author":"Van Derveer","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2026.111182_bib47","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41586-022-05483-6","article-title":"Filopodia are a structural substrate for silent synapses in adult neocortex","volume":"612","author":"Vardalaki","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2026.111182_bib48","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1073\/pnas.0700384104","article-title":"High-speed mapping of synaptic connectivity using photostimulation in Channelrhodopsin-2 transgenic mice","volume":"104","author":"Wang","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2026.111182_bib49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1113\/jphysiol.1995.sp020792","article-title":"Modulation by magnesium of the affinity of NMDA receptors for glycine in murine hippocampal neurones","volume":"486","author":"Wang","year":"1995","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2026.111182_bib50","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1152\/physiolgenomics.00006.2019","article-title":"Medial prefrontal cortex in neurological diseases","volume":"51","author":"Xu","year":"2019","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.neuropharm.2026.111182_bib51","article-title":"Advances in the treatment of cognitive impairment in schizophrenia: targeting NMDA receptor pathways","volume":"25","author":"Zhang","year":"2024","journal-title":"Int. J. Mol. Sci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:54:48Z","timestamp":1792788888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826003576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":51,"alternative-id":["S0028390826003576"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111182","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycine transporter 1 inhibitor, bitopertin, changes excitatory and inhibitory network connectivity in mouse medial prefrontal cortex","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111182","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111182"}}